- Home
- UP vs MLYS Comparison
UP vs MLYS Comparison
Compare UP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UP
- MLYS
- Stock Information
- Founded
- UP 2013
- MLYS 2019
- Country
- UP United States
- MLYS United States
- Employees
- UP N/A
- MLYS N/A
- Industry
- UP Aerospace
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- UP Consumer Discretionary
- MLYS Health Care
- Exchange
- UP Nasdaq
- MLYS Nasdaq
- Market Cap
- UP 1.2B
- MLYS 1.0B
- IPO Year
- UP N/A
- MLYS 2023
- Fundamental
- Price
- UP $1.38
- MLYS $13.48
- Analyst Decision
- UP
- MLYS Strong Buy
- Analyst Count
- UP 0
- MLYS 4
- Target Price
- UP N/A
- MLYS $27.00
- AVG Volume (30 Days)
- UP 980.5K
- MLYS 783.9K
- Earning Date
- UP 08-07-2025
- MLYS 08-12-2025
- Dividend Yield
- UP N/A
- MLYS N/A
- EPS Growth
- UP N/A
- MLYS N/A
- EPS
- UP N/A
- MLYS N/A
- Revenue
- UP $772,533,000.00
- MLYS N/A
- Revenue This Year
- UP $174.46
- MLYS N/A
- Revenue Next Year
- UP N/A
- MLYS N/A
- P/E Ratio
- UP N/A
- MLYS N/A
- Revenue Growth
- UP N/A
- MLYS N/A
- 52 Week Low
- UP $0.74
- MLYS $8.24
- 52 Week High
- UP $4.59
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- UP 49.00
- MLYS 35.32
- Support Level
- UP $1.28
- MLYS $12.98
- Resistance Level
- UP $1.68
- MLYS $16.67
- Average True Range (ATR)
- UP 0.15
- MLYS 0.81
- MACD
- UP -0.03
- MLYS -0.33
- Stochastic Oscillator
- UP 33.33
- MLYS 13.56
About UP Wheels Up Experience Inc.
Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.